Akeso’s cancer therapy gets orphan status from US FDA

Investing.comTuesday, September 16, 2025 at 4:53:31 AM
Akeso's cancer therapy has received orphan drug designation from the US FDA, which can accelerate its development and approval process.
Editor’s Note: This designation is significant as it provides incentives for companies to develop treatments for rare diseases, potentially leading to faster access for patients in need.
— Curated by the World Pulse Now AI Editorial System

Was this article worth reading? Share it

Recommended Readings
Krystal Biotech stock jumps after FDA expands VYJUVEK label
PositiveFinancial Markets
Krystal Biotech's stock surged following the FDA's decision to expand the label for its product VYJUVEK. This expansion is expected to enhance the product's market potential and boost investor confidence.
Editor’s Note: The FDA's approval is a significant milestone for Krystal Biotech, as it not only validates the efficacy of VYJUVEK but also opens new avenues for treatment options. This could lead to increased sales and a stronger position in the biotech market.
Latest from Financial Markets
Senate Confirms Stephen Miran as Fed Governor
PositiveFinancial Markets
The Senate has confirmed Stephen Miran as a new governor of the Federal Reserve, a key position in shaping U.S. monetary policy.
Editor’s Note: This confirmation is significant as it impacts the direction of the Federal Reserve's policies, which can influence economic stability and growth in the U.S. economy.
Winter fuel payments fell by 9.3 million before U-turn
NegativeFinancial Markets
Recent official data reveals a significant drop of 9.3 million in the number of people receiving winter fuel payments due to government cuts that have now been reversed.
Editor’s Note: This situation highlights the impact of government policy changes on vulnerable populations, especially during the winter months when heating costs can be a burden. The reversal of cuts may provide some relief, but the initial drop raises concerns about the effectiveness of support systems.
Berenberg discloses dealings in Dalata Hotel Group shares
NeutralFinancial Markets
Berenberg has disclosed its transactions involving shares of Dalata Hotel Group, indicating its investment activities in the hospitality sector.
Editor’s Note: This disclosure is significant as it highlights Berenberg's interest in the hospitality industry, which can influence market perceptions and investor confidence in Dalata Hotel Group.
China's Tencent aims to raise $1 billion equivalent in dim sum bonds, sources say
PositiveFinancial Markets
Tencent is reportedly looking to raise $1 billion through dim sum bonds, which are yuan-denominated bonds issued outside of China. This move highlights the company's strategy to diversify its funding sources.
Editor’s Note: This is significant as it reflects Tencent's ongoing efforts to strengthen its financial position and adapt to changing market conditions. Raising funds through dim sum bonds can also enhance its international presence and appeal to global investors.
Fintel stock jumps 4% as HY revenue climbs 19% on acquisitions, subscriptions
PositiveFinancial Markets
Fintel's stock surged by 4% following a 19% increase in revenue, driven by acquisitions and subscriptions. This positive growth reflects the company's successful strategies in expanding its market presence.
Editor’s Note: This matters because it highlights Fintel's strong performance in a competitive market. The increase in revenue from acquisitions and subscriptions indicates effective business strategies, which could attract more investors and boost confidence in the company's future.
Trump Files $15 Billion Defamation Lawsuit Against The New York Times
NegativeFinancial Markets
Donald Trump has filed a $15 billion defamation lawsuit against The New York Times, claiming the publication has harmed his reputation. This legal action highlights ongoing tensions between Trump and the media.
Editor’s Note: This lawsuit is significant as it underscores the contentious relationship between Trump and major media outlets. It raises questions about freedom of the press and the implications of defamation claims in the political arena.